Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma

Overview

This phase II trial studies how well stereotactic body radiation therapy and aflibercept work in treating patients with uveal melanoma. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Aflibercept may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving stereotactic body radiation therapy followed by aflibercept may work better in treating patients with uveal melanoma.

Full Title of Study: “Phase II Randomized Trial of Stereotactic Radiotherapy (SRT) Followed by Intravitreal Aflibercept Injection for Patients With Ocular Melanoma”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: July 13, 2020

Detailed Description

PRIMARY OBJECTIVES:

I. To assess the percentage of patients able to successfully complete their prescribed treatment of radiation and intravitreal ziv-aflibercept (aflibercept) injection (IAI) with an acceptable level of toxicity.

SECONDARY OBJECTIVES:

I. To assess for reduction in the incidence of 2-year rates of radiation maculopathy, radiation papillopathy, functional vision preservation, radiation glaucoma, and to assess 2-year local control and progression-free survival.

Interventions

  • Radiation: Stereotactic Body Radiation Therapy
    • Undergo radiation
  • Biological: Ziv-Aflibercept
    • Given IV

Arms, Groups and Cohorts

  • Experimental: A. Stereotactic body radiation therapy, ziv-aflibercept
    • Patients undergo stereotactic body radiation therapy over 5 fractions every other week day during days 1-10. Patients then receive ziv-aflibercept IVI on the last day of radiation therapy and then every 2 months for up to 2 years in the absence of disease progression or unacceptable toxicity.
  • Experimental: B. Stereotactic body radiation therapy, ziv-aflibercept
    • Patients undergo stereotactic body radiation therapy as in arm A. Patients then receive ziv-aflibercept IVI on the last day of radiation therapy and then every 4 months for up to 2 years in the absence of disease progression or unacceptable toxicity.

Clinical Trial Outcome Measures

Primary Measures

  • Incidence of grade 3 or higher toxicity according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
    • Time Frame: Up to 2 years
    • Will be determined by patients who experience grade >= 3 toxicity related to stereotactic radiation therapy and/or intravitreal aflibercept. Will be tested using one-sided exact binomial test with alpha 0.05. The two arms will be combined for the primary analysis

Secondary Measures

  • Radiation maculopathy rate defined as ophthalmoscopic detection of macular edema perivascular sheathing
    • Time Frame: At 2 years
    • Will be estimated separately in each arm with the corresponding exact binomial 90% confidence interval.
  • Radiation papillopathy rate defined as ophthalmoscopic detection of peripapillary encircling nerve fiber layer infarction
    • Time Frame: At 2 years
    • Will be estimated separately in each arm with the corresponding exact binomial 90% confidence interval.

Participating in This Clinical Trial

Inclusion Criteria

  • Provide signed and dated informed consent form or have a Legally Authorized Representative (LAR) who can give consent
  • Willing to comply with all study procedures and be available for the duration of the study
  • Must be a candidate for radiation therapy
  • Karnofsky performance status (KPS) >= 60
  • Diagnosed with uveal melanoma either clinically or pathologically on biopsy
  • Uveal melanoma of one eye only
  • Localized uveal melanoma, with no evidence of metastasis
  • Women of childbearing potential must have a negative urine or serum pregnancy test within 14 days prior to enrollment

Exclusion Criteria

  • Tumor thickness more than 14 mm as measured by ultrasound
  • Active collagen vascular disease
  • Any contraindication to intravitreal injections including: elevated intraocular pressure, ocular or periocular infection, active intraocular inflammation, or other determined by treating physician
  • Known allergic reactions to components of intravitreal Aflibercept
  • Patients with known hypercoagulable syndromes
  • Prior radiation to the eye or brain
  • Life expectancy less than 6 months
  • Blind in both eyes
  • Patients unable to receive contrast enhanced brain magnetic resonance imaging (MRI)
  • Deaf in both ears
  • Patients have hypersensitivity to intravitreal Aflibercept
  • Patients is on or within 1 month of systemic anti-VEGF treatment
  • Patients who are candidates for brachytherapy
  • Patients for whom enucleation is standard of care
  • Pregnancy or active breastfeeding. Sexually active men or women of childbearing potential who are unwilling to practice adequate contraception prior to the initial dose/start of the first treatment, during the study, and for at least 3 months after the last dose. Adequate contraceptive measures include stable use of oral contraceptives or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device; bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus contraceptive sponge, foam, or jelly
  • Contraception is not required for men with documented vasectomy
  • Postmenopausal women must be amenorrheic for at least 12 months in order not to be considered of childbearing potential. Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Sidney Kimmel Cancer Center at Thomas Jefferson University
  • Collaborator
    • Regeneron Pharmaceuticals
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Wenyin Shi, MD, PhD, Principal Investigator, Sidney Kimmel Cancer Center at Thomas Jefferson University
  • Overall Contact(s)
    • Wenyin Shi, MD, PhD, (215) 955-6702, wenyin.shi@jefferson.edu

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.